As OpenAI marks its tenth birthday in December 2025, it can celebrate becoming one of the world’s leading companies, worth perhaps as much as US$1 trillion (£750 billion). But it started as a ...

In risk groups defined by American Urologic Association criteria, recurrences were reported in 8.9% of patients of the low-risk group, 11% of patients in the intermediate-risk group, 22% of those in ...

Recurrences of low-, intermediate-, or high-/very high-risk tumors were again low, intermediate, or high risk in 74%, 62%, and 44% of cases, respectively. Recurrent non-muscle invasive bladder cancer ...

Adding one year of IMFINZI treatment to Bacillus Calmette-Guérin (BCG) induction and maintenance therapy delivered an early and sustained disease-free survival benefit vs. BCG alone WILMINGTON, Del.-- ...

In Sarah Yuska’s sixth-grade science class at Monocacy Middle School in Frederick, Maryland, students are just finishing up learning about body systems—respiratory, circulatory, skeletal, and so on.

Non-qualified mortgages cater to those with nontraditional incomes or credit issues. These mortgages may offer lower initial payments but carry higher long-term costs. Non-QM loans don't meet CFPB ...

Abstract: This study addresses the problem of sliding mode control (SMC) for networked non-homogeneous hidden semi-Markov switching systems under semi-Markov kernel and cyber attacks, in which the ...

Employers across the country are taking disciplinary action against workers who mocked the assassination of Charlie Kirk, with many going as far as firing. At least eight companies and organizations ...

Optune Lua is now approved for use concurrently with PD-1/PD-L1 inhibitors in adult patients with unresectable advanced/recurrent NSCLC who progressed on or after platinum-based chemotherapy Ministry ...

Many people dream about leaving the place where they were born or currently live and pursuing a life abroad. Usually, such dreams involve not some random country, but one that seemingly calls to a ...

The FDA approved mitomycin intravesical solution (Zusduri) as a nonsurgical option for recurrent low-grade, intermediate-risk non-muscle invasive bladder cancer (NMIBC). The product won the indication ...

PRINCETON, N.J.--(BUSINESS WIRE)-- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, ...